A new study by Thomas Jefferson University neuroscientist Jay Schneider, PhD, suggests that the toxic effects of lead can be mitigated by attentive maternal care and an enriched environment in an animal model.

A new study led by Thomas Jefferson University researchers has revealed insights into how the eye handles inflammation, particularly in autoimmune uveitis, an inflammatory disease that bypasses the eye’s immune privilege and can damage healthy eye tissue.

Silva Markovic-Plese, MD, PhD and her team at Thomas Jefferson University have been studying RRMS for more than a decade. In a previous study, they noticed elevated levels of an immune chemical called, IL-11, in the cerebrospinal fluid surrounding the brain and spinal cord of RRMS patients. They wanted to explore why.

In a new paper, published in EMBO Reports, a team including Davide Trotti, PhD, a neuroscientist at Thomas Jefferson University, showed how altered glucose metabolism in the brain and spinal cord are damaging to motor neurons in preclinical models that carry the genetic C9-NRE mutation. 

Molecular biologist Yohei Kirino, PhD and his research team at Thomas Jefferson University has found that certain RNA molecules in people with tuberculosis are drastically different than those in healthy people.

In a recent study, Scott A. Waldman, MD, PhD, and his team discovered that a gut receptor protein called GUCY2C could prevent PD development by protecting against brain damage and toxic insult.

“Recessive Dystrophic Epidermolysis Bullosa (RDEB) is the worst disease you’ve probably never heard of,” says dermatology researcher, Andrew South, PhD. RDEB patients and their families know just how horrible it can be.

Neuroscientist Manuel Covarrubias, MD, PhD and his research assistant Qiansheng Liang, MD led a study published in Nature Communications that focused on Kv3 channels, the subclass of voltage-gated potassium channels that selectively bind AUT5.